Last reviewed · How we verify
AT-527 and Probenecid
AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid.
AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid. Used for COVID-19.
At a glance
| Generic name | AT-527 and Probenecid |
|---|---|
| Also known as | Bemnifosbuvir |
| Sponsor | Atea Pharmaceuticals, Inc. |
| Drug class | Antiviral, Uricosuric agent |
| Target | SARS-CoV-2 RNA-dependent RNA polymerase, Uric acid transporter |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
AT-527 works by inhibiting the RNA-dependent RNA polymerase of SARS-CoV-2, which is essential for the replication of the virus. Probenecid, on the other hand, increases the renal excretion of uric acid, making it a treatment for gout.
Approved indications
- COVID-19
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT-527 and Probenecid CI brief — competitive landscape report
- AT-527 and Probenecid updates RSS · CI watch RSS
- Atea Pharmaceuticals, Inc. portfolio CI